SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(D)
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): November 15,
BIOSPECIFICS TECHNOLOGIES CORP.
(Exact name of registrant as specified in its charter)
|(State or Other Jurisdiction
||(Commission File Number)
||(I.R.S. Employer |
||Identification No.) |
35 Wilbur Street Lynbrook, NY 11563
of Principal Executive Office) (Zip Code)
(Registrants telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[_] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
Throughout this Current Report on Form 8-K, the term
Company refers to BioSpecifics Technologies Corp.
ITEM 8.01 OTHER EVENTS
On November 15, 2012, the Company issued a press release
announcing that its Board of Directors has authorized the repurchase of up to $2
million of its outstanding common stock.
A press release regarding the announcement is attached hereto
as Exhibit 99.1.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|Date: November 15, 2012
||BIOSPECIFICS TECHNOLOGIES CORP.
||/s/ Thomas L. Wegman |
||Thomas L. Wegman |